1. Home
  2. SKT vs LEGN Comparison

SKT vs LEGN Comparison

Compare SKT & LEGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Tanger Inc.

SKT

Tanger Inc.

N/A

Current Price

$38.34

Market Cap

4.0B

Sector

Real Estate

ML Signal

N/A

Logo Legend Biotech Corporation

LEGN

Legend Biotech Corporation

N/A

Current Price

$15.26

Market Cap

4.6B

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
SKT
LEGN
Founded
1981
2014
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
4.0B
4.6B
IPO Year
1994
2020

Fundamental Metrics

Financial Performance
Metric
SKT
LEGN
Price
$38.34
$15.26
Analyst Decision
Hold
Buy
Analyst Count
11
14
Target Price
$40.80
★ $40.93
AVG Volume (30 Days)
722.1K
★ 2.5M
Earning Date
11-04-2026
11-10-2026
Dividend Yield
★ 3.25%
N/A
EPS Growth
N/A
N/A
EPS
★ 0.82
N/A
Revenue
N/A
N/A
Revenue This Year
$1.67
$38.78
Revenue Next Year
$3.38
$17.61
P/E Ratio
$46.90
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$31.13
$15.73
52 Week High
$42.53
$37.50

Technical Indicators

Market Signals
Indicator
SKT
LEGN
Relative Strength Index (RSI) 54.40 31.52
Support Level $34.97 N/A
Resistance Level $38.83 $19.92
Average True Range (ATR) 0.79 1.39
MACD -0.10 -0.73
Stochastic Oscillator 36.50 0.49

Price Performance

Historical Comparison
SKT
LEGN

About SKT Tanger Inc.

Tanger Inc is an owner and operator of outlet and open-air centers in the United States and Canada. It is a fully-integrated, self-administered and self-managed REIT, which focuses on developing, acquiring, owning, operating and managing outlet and open-air shopping centers. Its consolidated portfolio consisted of 31 outlet centers and 2 open-air lifestyle centers.

About LEGN Legend Biotech Corporation

Legend Biotech Corp is a clinical-stage biopharmaceutical company. It is engaged in the discovery and development of novel cell therapies for oncology and other indications. The firm's product candidate, LCAR-B38M/JNJ-4528, is a chimeric antigen receptor, or CAR, T cell therapy for the treatment of multiple myeloma. Geographically, the company generates a majority of its revenue from the United States of America. The company generates revenue from License and Collaboration revenue.

Share on Social Networks: